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Complications of Sclerotherapy for Esophageal Varices in Liver 
Transplant Candidates 
P. Pillay, T.E. Starzl, and D.H. Van Thiel 
ENDOSCOPIC sclerotherapy as the initial form of therapy for bleeding esophageal varices is consid-
ered to be the treatment of choice in many centers. While 
bleeding is usually effectively controlled, \,2 the long-term 
prognosis for such patients remains poor3 ,4 since progres-
sive hepatic deterioration often precipitated by the bleed-
ing episode frequently leads to an early death. 
In an attempt to prevent the onset of future bleeding 
episodes in cirrhotic patients prophylactic sclerotherapy 
has become popular. The disappointing results of various 
prophylactic surgical procedures for bleeding varices have 
encouraged further the widespread use of prophylactic 
sclerotherapy. Nonetheless, recent randomized controlled 
studies have not supported the universal use ofprophylac-
tic sclerotherapy.5,6 
The advent of orthotopic liver transplantation (OLT) as 
an effective means of treating end-stage liver disease 
(ESLD) has altered the long-term prognosis for many 
cirrhotic patients. 
A recent report from this center has reported that 
sclerotherapy for bleeding varices followed by 0 L T signif-
icantly improved survival of cirrhotic patients. 3 The com-
plications associated with sclerotherapy in potential liver 
transplant candidates and the effect of such complications 
on the outcome of OLT have not been addressed. This 
report indicates that sclerotherapy is associated with sig-
nificant morbidity that can influence the outcome ofOLT. 
MATERIALS AND METHODS 
Part of the evaluation of all transplant candidates includes an 
upper gastrointestinal endoscopy at which time any varices iden-
tified are graded. 
The varices were graded as follows: grade I, varices filling 25% 
or less of the air-distended lumen of the esophagus; grade II, 
varices filling 26% to 50% of the air-distended lumen of the 
esophagus; grade III, varices filling 51% to 75% of the air-
distended lumen of the esophagus; and grade IV, varices filling 
more than 76% of the air-distended lumen of the esophagus. 
Those with grade III or IV varices seen between July 1985 and 
December 1988 were included in this study as this group was 
enrolled in a study assessing the role of sclerotherapy in the 
management of esophageal varices. The technique employed for 
variceal sclerosis and the method of injection utilized have been 
described previously.7 Briefly, all procedures were performed 
under conscious sedation using intravenous (IV) midazolam (2 to 
10 mg) and meperidine (50 to 200 mg). An Olympus 2T fiberoptic 
endoscope was used and 4 mL of 5% sodium morrhuate was 
injected per injection using a free hand technique. Prophylactic 
sclerotherapy was performed on a fixed schedule on days 1, 4. 7, 
14, 21, and 28 and then weekly until all of the varices were 
obliterated and/or OLT was performed. Emergent sclerotherapy 
was undertaken only if the patients were: (I) acutely bleeding 
from varices and required more than 4 U of blood to maintain 
hemodynamic stability or (2) continuing to bleed despite IV 
Pitressin. The clinical and biochemical paremeters for patients on 
the medical and surgical service based on Childs criteria were 
evenly matched (Table I). 
The chi-square test was used to determine the statistical signif-
icance of differences in proportions. A P value of <.05 was 
considered to be significant. 
RESULTS 
During the 3.5-year period encompassing patient accrual 
for this study, a total of 1314 patients with grade III or 
grade IV varices were seen by the combined medical-
surgical transplant services. This group represented 44% 
of the total 2988 adult patients who were seen, evaluated, 
and ultimately accepted for OL T at this institution during 
the study period. 
Prophylactic sclerotherapy was performed on 648 of686 
(95.0%) patients admitted to the medical service while 
emergency sclerotherapy was performed on the remaining 
38 cases (5.0%). Of 628 patients admitted to the surgical 
services, 134 (21%) underwent emergent sclerotherapy 
based on the above criteria for an emergent procedure. 
The remaining 494 patients (79%) had no bleeding and 
received no sclerotherapy despite having endoscopically 
demonstrated grade III/IV esophageal varices. 
A comparison of the important features of the two 
groups of patients studied is shown in Table 2. Eighty-five 
percent (583) of the patients on the medical service and 
Table 1. Childs Criteria 
Childs 
criteria Medical (%) Surgical (%) 
A 10 12 
B 72 63 
C 18 25 
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Table 2. Outcome of Sclerotherapy in Medical and 
Surgical Patients 
Total Number' 
Prophylactic sclerotherapy 
Emergency sclerotherapy 
No sclerotherapy 
Survival to OL T 
Death before OL T 
Death due to bleeding 
Other deaths (multiorgan, 
hepatic failure, sepsis) 
'Total number, 1314 patients. 
tMedical Service, 686 patients admitted. 
'Surgical service, 628 patients admitted. 
§p <.05. 
Medical No. 
(%)t 
648 (94) 
38 (5.5) 
o 
583 (85) 
97 (14) 
18 (2.7) 
79 (11.5) 
Surgical No. 
(%)' 
o 
134 (21.3)§ 
494 (78.7) 
509 (81) 
119(19) 
89 (14)§ 
30 (4.7) 
81% (509) on the surgical service survived to receive 
transplants while 14% (97) of the patients on the medical 
service and 19% (119) of the patients on the surgical 
service died before aLT. A greater proportion of the 
surgical patients (21.3%) had emergent sclerotherapy than 
did those on the medical service (5.5%) (P < .01). The 
policy was to admit patients who presented with bleeding 
to the surgical service because of heavier staff coverage of 
this service and the greater availability of intensive care 
beds. On either the medical or surgical service, the sclero-
therapy was provided by the same gastroenterologists. 
The complications of sclerotherapy experienced in both 
the prophylactic and emergent sclerotherapy groups are 
shown in Table 3. A significantly higher complication rate 
was noted for emergent sclerotherapy than for prophylac-
tic sclerotherapy (P < .01). However, the total number of 
patients with complications in the prophylactic sclerother-
apy group was 81 (12.5%) of the patients so treated. It must 
be noted also that the sclerotherapy performed in the 
emergently treated group occurred under the difficult cir-
cumstances of active bleeding with poor visualization in 
desperately ill patients. 
The single most important factor that emerged from an 
analysis of the factors predisposing to complications was 
the presence of repeated injections over 36 to 48 hours. All 
patients in the emergent sclerotherapy group who perfo-
rated had a minimum of three sclerotherapy sessions over 
a period of 72 hours. Three esophageal perforations also 
occurred in the prophylactic sclerotherapy group. How-
ever, when the number of procedures, rather than the 
number of patients treated is considered, a much higher 
complication rate was apparent for the emergent sclero-
Table 3. Major Complications of Prophylactic and 
Emergency Sclerotherapy 
Esophageal stricture 
Bleeding esophageal ulcers 
Esophageal perforation 
Total 
Prophylactic 
(648) 
58(9%) 
20 (3.1%) 
3(0.5%) 
81 (12.5%) 
Emergency 
(172) 
96 (56%) 
18 (10.5%) 
5 (2.9%) 
119 (69.4%) 
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therapy group (96 of 490 procedures, 19.6%) as compared 
with the prophylactic sclerotherapy group (58 of 3468 
procedures, 1.7%) (P = <.00l). 
The development of a sclerotherapy complication in 
either group often resulted in a delay in OL T or death. In 
three cases, OLT was performed within 24 to 48 hours 
after emergent sclerotherapy. A high gastric perforation 
was discovered at the time of laparotomy in one of these 
patients. In the other two, an esophageal perforation 
contributed to the death of each but was not detected until 
the postmortem examination. 
Strictures and bleeding esophageal ulcers, occurring as a 
result of sclerotherapy, were treated conservatively with 
excellent results in most cases. Often bougienage was 
required for esophageal strictures. Sucralfate therapy was 
universally administered for esophageal ulcers. Hemor-
rhage from esophageal ulcers usually responded to nonsur-
gical treatment. However, formal esophago-gastrectomy 
to arrest bleeding was required in two cases following a 
successful liver transplant and one of these patients died. 
The other had a total esophogectomy and colon interposi-
tion performed 6 months later. 
DISCUSSION 
Endoscopic sclerotherapy has been recommended as the 
treatment of choice for bleeding esophageal varices2 ,7 but 
the long-term survival of such patients is dependent on 
their hepatic reserve as stratified by Childs classification 
and perhaps on the severity of the initial episode of 
variceal bleeding,7 
The majority of trials regarding the benefits of sclero-
therapy have been undertaken at centers where OL T is not 
available. Garrett et al3 from this institution have reported 
that sclerotherapy followed by OL T significantly improves 
overall patient survival. However, the complications asso-
ciated with sclerotherapy were not reported. 
Patients with ESLD who bleed often decompensate 
rapidly, Traditionally they are admitted to an intensive 
care unit and are treated by volume replacement to main-
tain hemodynamic stability, A Pitressin infusion is admin-
istered followed by emergent endoscopy both for diagnos-
tic and therapeutic purposes. These patients are often 
irrational with hepatic encephalopathy or alcohol with-
drawal symptoms combined with vomiting or retching and 
excessive coughing. Visualization of the esophagus and 
the source of bleeding is typically not easy. While precise 
identification of the source of the bleeding may be 
achieved, precise injection of the sclerosant is not. Thus, 
intramural injections are common and as a result the 
complication rate of emergent sclerotherapy is greater than 
that seen with elective sclerotherapy. 
If emergent sclerotherapy has a greater morbidity than 
prophylactic sclerotherapy in OL T patients, then what 
might be an alternative solution for such cases? The 
Sengstaken-Blakemore (S-B) tube is effective in control-
ling hemorrhage in 95% of cases, with only a few compli-
SCLEROTHERAPY COMPLICATIONS 
cations that are avoidable, if appropriate precautions and 
monitoring are utilized. 8 Based on the experience at the 
University of Pittsburgh, we would suggest that emergent 
sclerotherapy be avoided for patients who are obvious 
candidates for OLT and who are admitted to the hospital 
with major variceal bleeding. Instead, a S-B tube should be 
inserted to control the hemorrhage and an immediate alert 
for a donor organ should be put in effect. OL T should be 
performed within 48 to 72 hours. This action avoids the 
need to carry out aggressive emergent sclerotherapy and 
provides a solution for the underlying cause of the variceal 
hemorrhage. This approach has been utilized in six pa-
tients at this institution recently with an excellent outcome 
in all six. Clearly the limiting factor for such a course of 
action is the availability of suitable donor organs. At 
centers where OL T is routinely performed, such as the 
University of Pittsburgh, an appropriate donor organ is 
essentially always found within 72 hours. In earlier cases 
seen at this institution, OLT was carried out within 24 to 48 
hours after emergent sclerotherapy was performed for 
acute variceal bleeding. Excellent results were obtained 
from the OL T but important morbidity including esopha-
geal perforation, esophageal ulcers, and stricture forma-
tion were seen frequently. Clearly, not all centers have 
either the facilities or staff to perform OLT within 48 hours 
of a bleeding episode. Under the proper circumstances, 
however, temporary control with the S-B tube would 
appear to be a better solution than emergent sclerotherapy. 
Repeated sclerotherapy sessions (mean 3 to 4) per-
formed over a short period of time were found to be the 
single most important contributing factor to the subse-
quent development of sclerotherapy complications. Ulcer-
ations occur within a few hours of variceal injections and 
are fully established by 7 to 10 days.9 Thus, frequent 
reinjections of the same or nearby sites often result in 
extensive transmural injury. 
The role of prophylactic sclerotherapy in patients se-
lected for OLT also requires reassessment. In particular, 
494 patients (79%) admitted to the surgical service did not 
require any sclerotherapy. Thus, a substantial proportion 
of the patients who were treated prophylactically probably 
would not have bled and therefore do not require sclero-
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therapy. It must be remembered that patients treated 
prophylactically had no bleeding to begin with, and yet 
experienced a complication rate of approximately 13%. 
In the present study, the frequency of subsequent hem-
orrhage in patients who were not bleeding at the time of 
transplant evaluation was the same in the patients who had 
prophylactic sclerotherapy as in those who did not. The 
size of the varices in the two groups was similar. None-
theless, a greater number of emergency bleeding episodes 
(134 of 628) occurred in those not receiving prophylactic 
sclerotherapy compared with those who did (34 of 686). 
This was because patients who presented with bleeding 
were usually admitted to the service not systematically 
providing prophylactic sclerotherapy. 
In conclusion, the widespread use of prophylactic 
sclerotherapy for varices irrespective of varix size or the 
state of the patient's liver disease requires careful reas-
sessment before its universal acceptance. Even in expert 
hands, a substantial complication rate is experienced. 
Similarly, the role of emergency sclerotherapy under the 
difficult conditions of acute variceal hemorrhage also re-
quires reassessment. Alternative forms of treatment with 
an S-B tube followed by early OLT rather than emergent 
sclerotherapy for patients with poor hepatic reserve is 
advised. 
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